Hospira Injectable Drug Products Recalled due to Defective Glass Vials

Risk Managers and Pharmacy healthcare personnel are informed by the FDA that certain Hospira Injectable Drug Products are recalled because of visible particles embedded in the glass located at the neck of the vial which can cause adverse events.

Background of Hospira Injectable Drug Products

Certain injectable drug products, by Hospira, Inc, are used to treat various types of cancer.

These Injectable drug products are:

• carboplatin
• cytarabine
• paclitaxel
• methotrexate

They are packaged in vials and methotrexate is also used for the treatment of rheumatoid arthritis and psoriasis. These injectable drug products are distributed to wholesalers and direct customers.

FDA Alert on Hospira Injectable Drug Products

FDA’s reason for the recall is that there are visible particles embedded in the glass located at the neck of the vial of certain Hospira Injectable Drug Products. The particles can be dislodged in the solution and in case they are injected into a patient this can cause bleeding, chest pain and respiratory problems, among others.

Recommendation on Hospira Injectable Drug Products

“Anyone with an existing inventory in the United States should stop use and distribution, quarantine the product immediately, and call Stericycle at 1-888-628-0734 between the hours of 8am to 5pm EDT, Monday through Friday, to arrange for the return of the product.”

AttorneyOne.com is a free nationwide legal referral service. We are not a law firm. We help consumers find the best representation for their legal needs.